摘要
目的 观察CD4 4v6作为宫颈鳞癌新辅助化疗治疗敏感性预测指标的可行性。方法 对 2 4例宫颈鳞癌采用以顺铂为主联合羟基喜树碱、博来霉素方案进行术前 2个疗程的新辅助化疗 ,对化疗前的宫颈鳞癌组织进行如下检测 :以流式细胞术检测组织中CD4 4v6及DNA指数 ,研究二者与化疗疗效之间的关系。结果 化疗前宫颈鳞癌组织中CD4 4v6及DNA指数检测值分别为 0 .4 81± 0 .15 0、1.345± 0 .2 4 6 ;化疗后肿瘤病灶缩小程度平均为 0 .6 33± 0 .2 14 ,临床观察化疗有效率为 83.3% ;化疗后肿瘤病灶缩小程度与CD4 4v6之间呈显著负相关 (r=- 0 .85 3,P <0 .0 1) ,与DNA指数检测值无显著相关性 (r=- 0 .332 ,P >0 0 5 )。结论 CD4 4v6可以作为宫颈鳞癌新辅助化疗治疗敏感性预测指标 。
Objective To determine the feasibility of CD44v6 as a indication of the response to neoadjuvant chemotherapy(NAC) in cervical squamous carcinoma. Methods 24 patients with squamous carcinoma of the uterine cervix, were treated with two cycles of cisplatin combined with hydroxycamptothecine 、bleomycin regiman . Before NAC the expression of CD44v6 and DNA index (DI) were detected with flow cytometry . The relationship of the detection and the curative effect were analysed. Results CD44v6 and DNA index in tumor tissue were 0.481± 0.150、 1.345± 0.246; the volume of tumor focus reduced with 0.633± 0.214;clinical response ( 83.3%) were recorded ;reduction of tumor volume was reverse correlation to expression of CD44v6(r= -0.853,P< 0.01),and significant correlation to DNA index was not observed(r= -0.332,P> 0 05). Conclusion CD44v6 could be as a indicator of the response to neoadjuvant chemotherapy in cervical squamous carcinoma, which could offer reference to selective clinical treatment of NAC.
出处
《医药论坛杂志》
2004年第20期15-16,18,共3页
Journal of Medical Forum
